Wyeth More Optimistic On Medicare Rx As Plan Details Emerge
This article was originally published in The Pink Sheet Daily
Executive Summary
Medicare Rx plans will mimic managed care contracting system rather than Medicaid's preferred drug list structure, North American President Mahady predicts. Wyeth ends some Medicaid contracts for Protonix after states ask for deeper discounts on proton pump inhibitor.
You may also be interested in...
Protonix Average Price Increases By 8% As Wyeth Cuts Medicaid Contracts
Focus on key managed care accounts and elimination of some state contracts has resulted in an 8% weighted average price increase compared to first quarter 2004. Protonix shows 10% total prescription growth, but posts flat sales due to 9% inventory workdown.
Protonix Average Price Increases By 8% As Wyeth Cuts Medicaid Contracts
Focus on key managed care accounts and elimination of some state contracts has resulted in an 8% weighted average price increase compared to first quarter 2004. Protonix shows 10% total prescription growth, but posts flat sales due to 9% inventory workdown.
Protonix “Best Price” Reporting Subject Of Boston Prosecutor’s Subpoena
U.S. Attorney’s Office seeks documents dating back to January 2000 on Wyeth’s quarterly calculations of average manufacturer price and “best price” for tablet and intravenous formulations of the proton pump inhibitor, the company says in its 10-K filing.